Docoh
Loading...

CRVS Corvus Pharmaceuticals

Employees

Data from SEC filings
Employee count

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM


On June 15, 2021, Corvus Pharmaceuticals, Inc. (the “Company”) held its 2021 Annual Meeting of Stockholders (the “Annual Meeting”). Only stockholders of record at the close of business on April 19, 2021, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, there were 38,309,551 shares of the Company’s common stock outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, 27,719,139 shares of the Company’s common stock were voted in person or by proxy for the two proposals set forth below, each of which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 20, 2021.

The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows:

Proposal No. 1 — Election of Directors

The Company’s stockholders elected the Class II director nominees below to the Company’s Board of Directors to hold office until the 2024 Annual Meeting of Stockholders or until their respective successors are elected and qualified or appointed, or the earlier of their death, resignation or removal.

Class II Director NomineesVotes ForVotes WithheldBroker Non-Votes
Scott W. Morrison20,548,120169,5727,001,447
Edith P. Mitchell, M.D.20,572,477145,2157,001,447


Proposal No. 2 — Ratification of Selection of Independent Registered Accounting Firm

The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLC as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021.

Votes ForVotes AgainstAbstain
27,550,16747,149121,823